Volume 72, Issue 5, Pages (November 2017)

Slides:

Advertisements

Similar presentations

Volume 56, Issue 5, Pages (November 2009)

Advertisements

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 6, Pages (December 2016)

Volume 61, Issue 5, Pages (May 2012)

Volume 70, Issue 4, Pages (October 2016)

Volume 73, Issue 1, Pages (January 2018)

Volume 70, Issue 5, Pages (November 2016)

Let the Games Begin (with EAU Approval)

Volume 71, Issue 5, Pages (May 2017)

Prostate Cancer Epidemic in Sight?

Volume 68, Issue 4, Pages (October 2015)

Volume 68, Issue 1, Pages (July 2015)

The Global Risk of Bladder Cancer: Let's Just Do Something About It!

Volume 67, Issue 2, Pages (February 2015)

Volume 54, Issue 4, Pages (October 2008)

Volume 68, Issue 5, Pages (November 2015)

Volume 73, Issue 2, Pages (February 2018)

Volume 63, Issue 6, Pages (June 2013)

Prostate Cancer Detection: A View of the Future

Volume 54, Issue 5, Pages (November 2008)

Volume 67, Issue 3, Pages (March 2015)

Volume 70, Issue 4, Pages (October 2016)

Next-generation Sequencing of Urologic Cancers: Next Is Now

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 69, Issue 6, Pages (June 2016)

Volume 67, Issue 6, Pages (June 2015)

Volume 71, Issue 6, Pages (June 2017)

Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay Alba Torres, Mohammed Alshalalfa, Scott.

Volume 64, Issue 6, Pages (December 2013)

Prostate Cancer Epidemic in Sight?

Volume 72, Issue 5, Pages (November 2017)

Global Burden of Urologic Cancers, 1990–2013

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 74, Issue 2, Pages (August 2018)

Volume 53, Issue 4, Pages (April 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 62, Issue 4, Pages (October 2012)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Tillmann Loch, Pat Fox Fulgham European Urology

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Physical Activity and Survival After Prostate Cancer

Volume 50, Issue 5, Pages (November 2006)

Volume 58, Issue 3, Pages (September 2010)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer

Testicular Cancer Variations in Time and Space in Europe

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

European Urology Oncology

Volume 59, Issue 4, Pages (April 2011)

Volume 75, Issue 3, Pages (March 2019)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Epidemiology of Renal Cell Carcinoma

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 51, Issue 2, Pages (February 2007)

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 72, Issue 5, Pages 845-852 (November 2017) Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens Paul L. Nguyen, Zaid Haddad, Ashley E. Ross, Neil E. Martin, Samineh Deheshi, Lucia L.C. Lam, Jijumon Chelliserry, Jeffrey J. Tosoian, Tamara L. Lotan, Daniel E. Spratt, Radka S. Stoyanova, Sanoj Punnen, Kaye Ong, Christine Buerki, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Kasra Yousefi, Voleak Choeurng, Elai Davicioni, Bruce J. Trock, Christopher J. Kane, Alan Pollack, John W. Davis, Felix Y. Feng, Eric A. Klein European Urology Volume 72, Issue 5, Pages 845-852 (November 2017) DOI: 10.1016/j.eururo.2017.05.009 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 C-index for metastasis at 5-yr post-Bx. † C-index of the combined models was corrected for optimism. CAPRA=Cancer of the Prostate Risk Assessment; NCCN=National Comprehensive Cancer Network. European Urology 2017 72, 845-852DOI: (10.1016/j.eururo.2017.05.009) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Cumulative incidence curves for Decipher, Cancer of the Prostate Risk Assessment (CAPRA), and National Comprehensive Cancer Network (NCCN) for metastasis endpoint. The dashed gray line represents the cohort average for metastasis risk. European Urology 2017 72, 845-852DOI: (10.1016/j.eururo.2017.05.009) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 3 Cumulative incidence curves for Decipher, Cancer of the Prostate Risk Assessment (CAPRA), and National Comprehensive Cancer Network (NCCN) for prostate cancer-specific mortality (PCSM) endpoint. The dashed gray line represents the cohort average for PCSM risk. European Urology 2017 72, 845-852DOI: (10.1016/j.eururo.2017.05.009) Copyright © 2017 European Association of Urology Terms and Conditions